Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial

(2016) Julio Rosenstock et al.   DIABETES CARE

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

(2016) Vanita R. Aroda et al.   DIABETES CARE

Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial

(2016) Julio Rosenstock et al.   DIABETES CARE

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes

(2016) Ildiko Lingvay et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36-week, randomized, double-blind, parallel-group trial

(2016) Yutaka Seino et al.   Journal of Diabetes Investigation

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial

(2015) A. Ahmann et al.   DIABETES OBESITY & METABOLISM

Clinical Effectiveness of Liraglutide Across Body Mass Index in Patients with Type 2 Diabetes in the United States: A Retrospective Cohort Study

(2014) Abhishek S. Chitnis et al.   ADVANCES IN THERAPY

Lixisenatide Treatment for Older Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetics: Meta-Analysis of Five Randomized Controlled Trials

(2014) Markolf Hanefeld et al.   ADVANCES IN THERAPY

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

(2014) Julio Rosenstock et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)

(2014) John B. Buse et al.   DIABETES CARE

Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes

(2014) Michaela Diamant et al.   DIABETES CARE

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)

(2014) C. Mathieu et al.   DIABETES OBESITY & METABOLISM

The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial

(2014) W. Lane et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of lixisenatide in elderly ( ≥65 years old) and very elderly ( ≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme

(2014) Denis Raccah et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes

(2014) Ning Shao et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)

(2014) Helena M. de Wit et al.   DIABETOLOGIA

Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis

(2014) Conrad Eng et al.   LANCET

Weight Change in Patients with Type 2 Diabetes Starting Basal Insulin Therapy: Correlates and Impact on Outcomes

(2014) Charles F. Shaefer et al.   POSTGRADUATE MEDICINE

GLP-1 receptor agonists: a review of head-to-head clinical studies

(2014) Jennifer M. Trujillo et al.   Therapeutic Advances in Endocrinology and Metabolism

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

(2013) John B. Buse et al.   ANNALS OF INTERNAL MEDICINE

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin

(2013) Matthew C. Riddle et al.   DIABETES CARE

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine

(2013) Matthew C. Riddle et al.   DIABETES CARE

GLP-1R agonist therapy for diabetes

(2013) Susan L. Samson et al.   Current Opinion in Endocrinology Diabetes and Obesity

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes

(2012) Yuya Fujishima et al.   Cardiovascular Diabetology

Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity

(2012) Chun-jun Li et al.   Cardiovascular Diabetology

GLP-1 based therapies: differential effects on fasting and postprandial glucose

(2012) M.S. Fineman et al.   DIABETES OBESITY & METABOLISM

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)

(2012) Y. Seino et al.   DIABETES OBESITY & METABOLISM

Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations

(2012) R. Pencek et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

(2012) Juris J. Meier   Nature Reviews Endocrinology

Exenatide Twice Daily: Analysis of Effectiveness and Safety Data Stratified by Age, Sex, Race, Duration of Diabetes, and Body Mass Index

(2012) Richard Pencek et al.   POSTGRADUATE MEDICINE

Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes ≥65 and

(2011) Bruce W. Bode et al.   American Journal Geriatric Pharmacotherapy

Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes

(2011) Stuart A. Ross et al.   CURRENT MEDICAL RESEARCH AND OPINION

Proportion of patients at HbA1c target

(2011) K. Esposito et al.   DIABETES OBESITY & METABOLISM

Comparison of 2 Intensification Regimens with Rapid-Acting Insulin Aspart in Type 2 Diabetes Mellitus Inadequately Controlled by Once-Daily Insulin Detemir and Oral Antidiabetes Drugs: The Step-Wise Randomized Study

(2011) Luigi Meneghini et al.   Endocrine Practice

A Stepwise Approach to Insulin Therapy in Patients with Type 2 Diabetes Mellitus and Basal Insulin Treatment Failure

(2011) Mayer Davidson et al.   Endocrine Practice